Item request has been placed!
×
Item request cannot be made.
×
Processing Request
CYTOPIA BEGINS SECOND PHASE II STUDY IN BRAIN CANCER.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- الموضوع:
- نبذة مختصرة :
The article reports on the commencement of enrolment for Melbourne, Victoria-based Cytopia Limited's Phase Ib/II study of CYT997, the company's novel vascular-disrupting antineoplastic agent. The drug is aimed at patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).
No Comments.